查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
充血性心臟衰竭 (CHF) 市场 - 成长、未来前景、竞争分析，2023-2031 年
市场调查报告书
商品编码
1355788

充血性心臟衰竭 (CHF) 市场 - 成长、未来前景、竞争分析，2023-2031 年

Congestive Heart Failure (CHF) Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

充血性心臟衰竭 (CHF) 也称为心臟衰竭，是一种慢性疾病，会降低心臟有效泵血的能力。 当心肌变弱或受损，导致含氧血液供应不足以满足身体需求时，就会发生这种情况。 结果，液体积聚在身体的各个部位，导致呼吸短促、疲劳、脚和脚踝肿胀（水肿）以及身体活动困难等症状。 预计 2023 年至 2031 年期间，充血性心臟衰竭治疗药物市场将以 14.5% 的复合年增长率成长。 心臟病的流行加上医疗技术的进步将维持对有效的慢性心臟衰竭治疗的需求。 监管挑战仍将持续，公司将需要应对复杂的审批流程。 按类别和销售管道进行市场细分对于满足不同的患者需求仍然很重要。

心臟病盛行率增加

CHF 治疗市场的主要驱动力之一是全球心臟病盛行率的上升。 世界卫生组织（WHO）将心血管疾病列为全球第一大死因。 充血性心臟衰竭盛行率不断上升，久坐的生活方式和不良饮食等因素加剧了这种情况，显着增加了对有效治疗方案的需求。 随着人口老化，心臟病相关疾病的负担预计将增加，进一步推动市场成长。

医疗技术的进步

由于医疗技术的进步，CHF的治疗状况已彻底改变。 药物输送系统、个人化医疗方法和新型化合物的开发的创新显着改善了患者的治疗效果。 特别是，沙库巴曲/缬沙坦（Entrest）的推出代表了射血分数降低心臟衰竭治疗的突破。 这些进步不仅提高了治疗的有效性，而且还扩大了医疗保健专业人员和患者可用的治疗选择。

重视早期诊断、早期治疗

促进心臟病的早期诊断和及时治疗的努力正在对 CHF 治疗市场产生积极影响。 医疗保健组织和政府努力提高人们对心臟健康的认识以及早期干预的好处，从而提高了患者的认识。 心臟衰竭的早期发现使医疗保健专业人员能够实施预防疾病进展和改善整体生活品质的治疗策略。 这些努力的累积正在推动CHF治疗药物的需求。

严格的监理要求

CHF治疗市场在不断成长的同时，也面临严格监管要求带来的挑战。 新药的开发和获得批准的过程复杂且耗时。 FDA 和 EMA 等监管机构对新药候选物施加严格的安全性和有效性标准，从而延长了开发时间并增加了成本。 对于中小型製药公司来说，适应监管环境尤其困难，并且限制了市场成长。

血管张力素 2 受体拮抗剂依类别主导市场

2022 年，血管张力素 2 受体阻断剂 (ARB) 的销售额创下最高纪录。 血管紧张素 2 受体拮抗剂是透过阻断血管紧张素 II 的作用的药物，血管紧张素 II 是一种导致血管收缩和液体滞留的激素。 透过抑制这些作用，ARB 可以放鬆血管、降低血压、减轻心臟负担。 ARB 通常用于治疗 CHF 和高血压等相关疾病。 它常与ACE抑制剂、β受体阻断剂、利尿剂等其他药物合併使用，为心臟衰竭患者提供综合治疗。 这些药物可以改善症状，增加心臟的泵血能力，并有助于更好的整体疾病管理。 血管张力素 2 受体拮抗剂由于其既定疗效和广泛使用，历来在 CHF 治疗市场上产生了可观的收入。 血管张力素 2 受体拮抗剂是许多患者治疗方案的重要组成部分，因为它们可以解决心臟衰竭治疗的多个方面。 然而，值得注意的是，每个药物类别产生的收入可能会根据市场动态、定价、患者偏好和新治疗方案的出现等因素而波动。

医院药局透过分销管道主导市场

2022年，医院药局的销售额最高。 医院药局是医院内为住院病人和门诊病人配药的医疗机构。 这些药房在为包括慢性心臟衰竭在内的急性疾病患者提供即时获得基本药物方面发挥着重要作用。 医院药局通常储备多种药物，包括心臟衰竭药物，并由医疗专业人员监督，以确保患者接受正确的药物和剂量。 对于患有严重心臟衰竭或其併发症的住院患者，可以直接静脉注射或肌肉注射，医院药房也接待此类患者。

北美仍处于世界领先地位

CHF 治疗市场的地理趋势因地区而异。 由于医疗基础设施发展的进步、老年人口的增加以及高血压和糖尿病等危险因素的流行等综合因素，复合年增长率最高的地区是亚太地区。 北美由于其完善的医疗保健系统、高额医疗支出以及对研发活动的重视，始终保持最高的销售份额。

竞争趋势与主要策略

在竞争激烈的 CHF 药物市场中，领先公司正在采取各种策略来维持其市场地位并推动创新。 Bayer AG, Novartis AG, Merck &co., Inc., Astrazeneca, Bristol-Myers Squibb Company, Amgen Inc., BoehringerIngelheiminternationalGmbh, Pfizer, Inc., Johnson &Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Novo Nordiska/S等着名公司，如诺和诺德公司(Novo Nordiska/S and Company) 一直在寻求合併、收购、合作伙伴关係和产品发布，以扩大其产品组合併加强其市场覆盖范围。 这些公司也大力投资研发，专注于精准治疗、个人化医疗方法和改善病患治疗效果。

目录

第一章前言

  • 报告内容
    • 报告的目的
    • 目标受众
    • 提供的主要产品
  • 市场区隔
  • 调查方法
    • 第一阶段-二次调查
    • 第二阶段 - 初步调查
    • 第三阶段-专家评审
    • 先决条件
    • 采用的方法

第 2 章执行摘要

第 3 章充血性心臟衰竭 (CHF) 市场：竞争分析

  • 主要供应商的市场地位
  • 供应商采取的策略
  • 主要产业战略
  • 层级分析：2022 年与 2031 年

第 4 章充血性心臟衰竭 (CHF) 市场：宏观分析与市场动态

  • 简介
  • 2021-2031 年世界充血性心臟衰竭 (CHF) 市场价值
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 主要挑战
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析

第 5 章充血性心臟衰竭 (CHF) 市场：依药物类别 2021-2031

  • 市场概览
  • 成长/利润分析：2022 年与 2031 年
  • 市场区隔
    • ACE抑制剂
    • 血管张力素2受体阻断剂
    • β受体阻断剂
    • 利尿剂
    • 醛固酮拮抗剂
    • 正性肌力药
    • 其他

第 6 章充血性心臟衰竭 (CHF) 市场：依通路划分，2021-2031 年

  • 市场概览
  • 成长/利润分析：2022 年与 2031 年
  • 市场区隔
    • 医院药房
    • 零售药局
    • 网路药局

第 7 章北美充血性心臟衰竭 (CHF) 市场 2021-2031

  • 市场概览
  • 充血性心臟衰竭 (CHF) 市场：依药物类别划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：依通路划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：按地区划分 2021-2031 年
    • 北美
      • 美国
      • 加拿大
      • 其他北美地区

第 8 章英国与欧盟充血性心臟衰竭 (CHF) 市场 2021-2031

  • 市场概览
  • 充血性心臟衰竭 (CHF) 市场：依药物类别划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：依通路划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：按地区划分 2021-2031 年
    • 英国和欧盟
      • 英国
      • 德国
      • 西班牙
      • 义大利
      • 法国
      • 其他欧洲地区

第 9 章亚太地区充血性心臟衰竭 (CHF) 市场 2021-2031

  • 市场概览
  • 充血性心臟衰竭 (CHF) 市场：依药物类别划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：依通路划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：按地区划分 2021-2031 年
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区

第 10 章 2021-2031 年拉丁美洲充血性心臟衰竭 (CHF) 市场

  • 市场概览
  • 充血性心臟衰竭 (CHF) 市场：依药物类别划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：依通路划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：按地区划分 2021-2031 年
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地区

第 11 章中东与非洲充血性心臟衰竭 (CHF) 市场 2021-2031

  • 市场概览
  • 充血性心臟衰竭 (CHF) 市场：依药物类别划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：依通路划分，2021-2031 年
  • 充血性心臟衰竭 (CHF) 市场：按地区划分 2021-2031 年
    • 中东/非洲
      • 海湾合作委员会
      • 非洲
      • 其他中东/非洲地区

第十二章公司简介

  • Bayer AGNovartis AG
  • Merck & co. Inc.
  • Astrazeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • BoehringerIngelheiminternationalGmbh
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Otsuka Pharmaceutical Co. Ltd.
  • Eli Lilly and Company
  • Novo Nordiska/S
  • 其他主要公司
Product Code: 139808-09-23

Congestive heart failure (CHF), also known as heart failure, is a chronic medical condition in which the heart's ability to pump blood efficiently is compromised. This condition occurs when the heart muscles become weakened or damaged, leading to an inadequate supply of oxygenated blood to meet the body's needs. As a result, fluid may accumulate in various parts of the body, causing symptoms such as shortness of breath, fatigue, swelling in the legs and ankles (edema), and difficulty performing physical activities. The congestive heart failure drug market is expected to grow at a CAGR of 14.5% during the forecast period of 2023 to 2031. The prevalence of heart diseases, coupled with ongoing advancements in medical technology, will sustain the demand for effective CHF treatments. Regulatory challenges will persist, requiring companies to navigate complex approval processes. Market segmentation by class and distribution channels will remain instrumental in catering to diverse patient needs.

Rising Prevalence of Heart Diseases

One of the primary drivers of the CHF drugs market is the escalating prevalence of heart diseases worldwide. The World Health Organization (WHO) has identified cardiovascular diseases as the leading cause of mortality globally. The growing incidence of congestive heart failure, exacerbated by factors like sedentary lifestyles and poor dietary habits, has substantially increased the demand for effective treatment options. As the population ages, the burden of heart-related ailments is projected to rise, further fueling the market's growth.

Advancements in Medical Technology

The landscape of CHF treatment has been revolutionized by advancements in medical technology. Innovations in drug delivery systems, personalized medicine approaches, and the development of novel drug compounds have significantly improved patient outcomes. Notably, the introduction of sacubitril/valsartan (Entresto) has marked a breakthrough in managing heart failure with reduced ejection fraction. Such advancements have not only enhanced the efficacy of treatments but have also expanded the treatment options available to healthcare providers and patients.

Focus on Early Diagnosis and Treatment

Efforts to promote early diagnosis and timely treatment of heart conditions have had a positive impact on the CHF drugs market. Initiatives by healthcare organizations and governments to raise awareness about heart health and the benefits of early intervention have led to increased patient awareness. By identifying heart failure in its early stages, medical professionals can implement treatment strategies that prevent disease progression and improve overall quality of life. These efforts have collectively driven the demand for CHF drugs.

Stringent Regulatory Requirements

While the CHF drugs market has experienced growth, it has also encountered challenges posed by stringent regulatory requirements. The process of developing and gaining approval for new drugs is complex and time-consuming. Regulatory agencies such as the FDA and EMA impose rigorous safety and efficacy standards on new drug candidates, leading to prolonged development timelines and elevated costs. Navigating the regulatory landscape can be particularly challenging for smaller pharmaceutical companies, acting as a restraint on market growth.

Angiotensin 2 Receptor Blockers Dominated Market by Class

In 2022, Angiotensin 2 Receptor Blockers (ARBs) held highest revenue. Angiotensin 2 Receptor Blockers are a class of medications that work by blocking the effects of the hormone angiotensin II, which can lead to blood vessel constriction and fluid retention. By blocking these effects, ARBs help relax blood vessels, reduce blood pressure, and decrease the workload on the heart. ARBs are commonly prescribed to manage CHF and related conditions, such as hypertension. They are often used in combination with other medications, such as ACE inhibitors, beta blockers, and diuretics, to provide comprehensive treatment for heart failure patients. These medications can help improve symptoms, enhance the heart's pumping efficiency, and overall contribute to better management of the condition. Due to their established efficacy and widespread use, Angiotensin 2 Receptor Blockers have historically generated substantial revenue in the CHF drugs market. Their ability to address multiple aspects of heart failure management makes them a critical component of treatment regimens for many patients. However, it's important to note that the revenue generated by each drug class can vary based on factors such as market dynamics, pricing, patient preferences, and the emergence of newer treatment options.

Hospital Pharmacies Dominates Market by Distribution Channel

In 2022, Hospital Pharmacies held highest revenue. Hospital Pharmacies are healthcare facilities within hospitals that dispense medications to both inpatients and outpatients. These pharmacies play a crucial role in providing immediate access to essential medications for patients with acute conditions, including CHF. Hospital Pharmacies often have a wide range of medications available, including those for treating heart failure, and they ensure that patients receive the right medications and dosages under the supervision of healthcare professionals. Patients hospitalized due to severe CHF or related complications may have their medications administered directly through intravenous (IV) or intramuscular (IM) injections, which are facilitated by Hospital Pharmacies.

North America Remains as the Global Leader

The geographic trends in the CHF drugs market reveal varying patterns across regions. The region with the highest CAGR is Asia-Pacific, driven by a combination of factors such as increasing healthcare infrastructure development, a rising geriatric population, and the prevalence of risk factors like hypertension and diabetes. North America has consistently held the highest revenue share, attributed to its well-established healthcare systems, significant healthcare expenditure, and a robust focus on research and development activities.

Competitive Trends and Key Strategies

In the fiercely Competitive Landscape of the CHF drugs market, leading players have adopted diverse strategies to maintain their market presence and drive innovation. Notable players like Bayer AG,Novartis AG, Merck & co., Inc., Astrazeneca, Bristol-Myers Squibb Company, Amgen Inc., BoehringerIngelheiminternationalGmbh, Pfizer, Inc., Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, and Novo Nordiska/S have pursued mergers, acquisitions, collaborations, and product launches to expand their portfolios and enhance their market reach. These companies are also investing heavily in research and development endeavors, focusing on precision therapies, personalized medicine approaches, and improved patient outcomes.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofCongestive Heart Failure (CHF) market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Congestive Heart Failure (CHF) market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Congestive Heart Failure (CHF) market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Congestive Heart Failure (CHF) market?
  • Which is the largest regional market for Congestive Heart Failure (CHF) market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Congestive Heart Failure (CHF) market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Congestive Heart Failure (CHF) market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Congestive Heart Failure (CHF) Market
  • 2.2. Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022 (US$ Million)
  • 2.3. Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022 (US$ Million)
  • 2.4. Global Congestive Heart Failure (CHF) Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Congestive Heart Failure (CHF) Market: Competitive Analysis

  • 3.1. Market Positioning of Key Congestive Heart Failure (CHF) Market Vendors
  • 3.2. Strategies Adopted by Congestive Heart Failure (CHF) Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Congestive Heart Failure (CHF) Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Congestive Heart Failure (CHF) Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. ACE Inhibitors
    • 5.3.2. Angiotensin 2 Receptor Blockers
    • 5.3.3. Beta Blockers
    • 5.3.4. Diuretics
    • 5.3.5. Aldosterone Antagonists
    • 5.3.6. Inotropes
    • 5.3.7. Others

6. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies

7. North America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 7.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 7.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 7.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

8. UK and European Union Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 8.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 8.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 8.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

9. Asia Pacific Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 9.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 9.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.4.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.5.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 9.4.1.6.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

10. Latin America Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 10.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 10.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 10.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

11. Middle East and Africa Congestive Heart Failure (CHF) Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
  • 11.3. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
  • 11.4.Congestive Heart Failure (CHF) Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.1.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.2.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Congestive Heart Failure (CHF) Market: By Drug Class, 2021-2031, USD (Million)
        • 11.4.1.3.2. Congestive Heart Failure (CHF) Market: By Distribution Channel, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Bayer AG,Novartis AG
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Merck & co., Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Astrazeneca
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Bristol-Myers Squibb Company
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Amgen Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. BoehringerIngelheiminternationalGmbh
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Pfizer, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Johnson & Johnson Services, Inc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Otsuka Pharmaceutical Co., Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Eli Lilly and Company
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Novo Nordiska/S
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. Other Notable Players
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 2 Global Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 3 North America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 4 North America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 5 U.S. Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 6 U.S. Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 7 Canada Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 8 Canada Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 13 UK Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 14 UK Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 15 Germany Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 16 Germany Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 17 Spain Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 18 Spain Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 19 Italy Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 20 Italy Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 21 France Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 22 France Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 25 Asia Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 26 Asia Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 27 China Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 28 China Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 29 Japan Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 30 Japan Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 31 India Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 32 India Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 33 Australia Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 34 Australia Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 35 South Korea Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 36 South Korea Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 37 Latin America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 38 Latin America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 39 Brazil Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 40 Brazil Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 41 Mexico Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 42 Mexico Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 47 GCC Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 48 GCC Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 49 Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 50 Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market By Drug Class, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market By Distribution Channel, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Congestive Heart Failure (CHF) Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Congestive Heart Failure (CHF) Market: Quality Assurance
  • FIG. 5 Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022
  • FIG. 6 Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022
  • FIG. 7 Global Congestive Heart Failure (CHF) Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Congestive Heart Failure (CHF) Market, 2022

FIG. 9Market Positioning of Key Congestive Heart Failure (CHF) Market Players, 2022

FIG. 10Global Congestive Heart Failure (CHF) Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 11 Global Congestive Heart Failure (CHF) Market, By Drug Class, 2022 Vs 2031, %
  • FIG. 12 Global Congestive Heart Failure (CHF) Market, By Distribution Channel, 2022 Vs 2031, %
  • FIG. 13 U.S. Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 20 France Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 22 China Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 24 India Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Congestive Heart Failure (CHF) Market (US$ Million), 2021 - 2031